SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (the “Company” or “BSD”) announced today that 21st Century Oncology has purchased the BSD-500 Hyperthermia System (BSD-500). 21st Century Oncology is a leading provider of radiation therapy centers and operates 98 freestanding and hospital-based centers in the US. 21st Century Oncology centers provide a full spectrum of advanced treatments to cancer patients. Additionally, 21st Century Oncology's doctors come from some of the most prestigious and recognized medical training centers and universities in the world and their senior radiation oncologists are nationally recognized for excellence and leadership in the field of radiation oncology. The purchase of the BSD-500 by 21st Century Oncology significantly increases the number of patients who will have access to hyperthermia treatment.
"Thanks to dedicated scientists and clinicians, we now have good clinical data on hyperthermia treatment and an excellent delivery device to offer our patients," said Alan Brown, Jr., MD, Radiation Oncologist in Fort Myers, Florida. "The addition of hyperthermia to the services at 21st Century Oncology provides patients a greater opportunity for innovative treatment options close to home. It also adds another weapon to our arsenal in the battle with cancer. 21st Century Oncology is very excited to bring this technology to our patients and our network of doctors here in Southwest Florida and soon throughout our other locations."
About 21st Century Oncology
21st Century Oncology centers provide sophisticated technology, a high standard of quality patient care and service, and a competitive cost structure. The 21st Century Oncology's radiation therapy centers are clustered into regional networks in Alabama, Arizona, California, Delaware, Florida, Kentucky, Massachusetts, Maryland, Michigan, New Jersey, New York, Nevada, North Carolina, Rhode Island, and West Virginia. Ongoing clinical research is leading toward more effective cancer treatments, and 21st Century Oncology is committed to participating in that research.
About the BSD-500 Hyperthermia System
The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), which is the standard FDA approval required to market Class III medical devices in the United States, for the use of hyperthermia alone or in conjunction with radiation therapy for the treatment of certain tumors.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.